10-Q: Candel Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Candel Therapeutics reports a net loss of $8.2 million for the first quarter of 2024, with ongoing clinical trials and a focus on the development of CAN-3110 and the enLIGHTEN Discovery Platform.

Summary

• Candel Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $8.2 million for the three months ended March 31, 2024, compared to a net loss of $8.8 million for the same period in 2023.
• The company's cash and cash equivalents were $25.7 million as of March 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern for the one-year period following the date the financial statements are issued, requiring additional funding.
• Research and development expenses decreased to $4.1 million in Q1 2024 from $5.5 million in Q1 2023, primarily due to a reduction in employee-related expenses and clinical development costs.
• General and administrative expenses decreased to $3.8 million in Q1 2024 from $4.2 million in Q1 2023, mainly due to a decrease in employee-related expenses and insurance costs.
• The company has ongoing clinical trials for CAN-2409 in prostate cancer, non-small cell lung cancer, and pancreatic cancer, and for CAN-3110 in recurrent high-grade glioma.
• The company has received fast track designation from the FDA for CAN-2409 in NSCLC and pancreatic cancer, and for CAN-3110 in recurrent HGG.
• The company has also received orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.
• The company completed a corporate restructuring in the first quarter of 2024, incurring $0.7 million in severance costs.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and regulatory designations, the financial results and going concern warning create a negative sentiment. The need for additional funding and the inherent risks of drug development temper any optimism.

Positives

• The company has received fast track designation from the FDA for CAN-2409 in NSCLC and pancreatic cancer, and for CAN-3110 in recurrent HGG.
• The company has also received orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.
• The company expects to report topline data for the phase 3 prostate cancer trial and the phase 2 low-to-intermediate risk prostate cancer trial in the fourth quarter of 2024.
• The company will present topline overall survival data for Cohort 2 of the NSCLC trial at the ASCO Annual Meeting in June 2024.
• The company will present data regarding the feasibility and tolerability of multiple injections of CAN-3110 at the ASCO Annual Meeting in June 2024.

Negatives

• The company reported a net loss of $8.2 million for the first quarter of 2024.
• There is substantial doubt about the company's ability to continue as a going concern for the one-year period following the date the financial statements are issued, requiring additional funding.
• The company has incurred recurring losses since its inception and expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• The company's business is dependent on the success of CAN-2409, CAN-3110 and any other product candidates that it advances into the clinic.
• Preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of product candidates.
• The regulatory approval processes are lengthy, time-consuming and unpredictable.
• The company may not achieve broad market acceptance for its product candidates, even if approved.
• The company has incurred indebtedness, and may incur additional indebtedness, which could adversely affect its financial condition.
• The company's rights to develop and commercialize certain product candidates are subject to the terms and conditions of licenses granted by third parties.
• The company's manufacturing operations are transitioning to a third-party contract manufacturer, which may result in delays or expenses.
• The company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including dependence on key personnel, protection of proprietary technology, and compliance with government regulations.

Future Outlook

The company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future and will require additional funding to sustain operations beyond the next year. The company expects to report topline data for the phase 3 prostate cancer trial and the phase 2 low-to-intermediate risk prostate cancer trial in the fourth quarter of 2024. The company will present topline overall survival data for Cohort 2 of the NSCLC trial and data regarding the feasibility and tolerability of multiple injections of CAN-3110 at the ASCO Annual Meeting in June 2024.

Management Comments

• Based on our current operating plan and existing cash and cash equivalents, we determined that substantial doubt exists regarding our ability to continue as a going concern for the one-year period following the date these condensed consolidated financial statements are issued.
• To sustain its future operations beyond such one-year period, we will require additional funding.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on viral immunotherapies for cancer treatment, a field with increasing interest and development activity. The company faces competition from major pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as academic institutions and other research organizations.

Comparison to Industry Standards

• The company's financial results are typical for a clinical-stage biopharmaceutical company with no approved products, characterized by significant operating losses and reliance on external funding.
• The company's research and development expenses are consistent with other companies in the industry that are advancing product candidates through clinical trials.
• The company's cash position is relatively low compared to some of its peers, highlighting the need for additional funding.
• The company's reliance on third-party manufacturers is common in the industry, but it also introduces risks related to supply chain and quality control.
• The company's focus on viral immunotherapies is aligned with a growing trend in cancer treatment, but the regulatory pathway for these therapies is still evolving.

Management Changes

Legal Proceedings

• On December 15, 2022, Periphagen notified the company by letter of its claim that the company has failed to use commercially reasonable efforts to complete a human proof of concept clinical trial of an NT-3 Asset under an Exclusive License Agreement dated December 9, 2019 between the company and Periphagen.
• On January 13, 2023, the company filed a demand for arbitration against Periphagen with the American Arbitration Association, seeking a declaration that Periphagen's December 15 letter failed to comply with the dispute and escalation provisions in the Periphagen License Agreement.
• On March 10, 2023, Periphagen filed its answer and counterclaims to the company's demand for arbitration.
• On June 7, 2023, the parties entered into an amendment to the Exclusive License Agreement that resolved the dispute and resulted in termination of the arbitration without any financial impact.

Related Party Transactions

• The company has an exclusive licensing agreement with Ventagen, LLC, an entity owned in part by certain of the company's stockholders.
• The company has had lease agreements with Ellka Holdings, LLC, an entity owned and operated by certain of the company's stockholders and their family.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional funding and the volatility of the stock price.
• Employees may be affected by the company's restructuring and potential future changes in operations.
• Customers (potential patients) may benefit from the development of new therapies, but also face the risks associated with clinical trials and regulatory approval.
• Suppliers and creditors may be affected by the company's financial condition and ability to meet its obligations.

Next Steps

• The company expects to report topline data for the phase 3 prostate cancer trial and the phase 2 low-to-intermediate risk prostate cancer trial in the fourth quarter of 2024.
• The company will present topline overall survival data for Cohort 2 of the NSCLC trial at the ASCO Annual Meeting in June 2024.
• The company will present data regarding the feasibility and tolerability of multiple injections of CAN-3110 at the ASCO Annual Meeting in June 2024.
• The company will continue to seek additional funding to sustain its operations.

Key Dates

Keywords

Candel Therapeutics, CAN-2409, CAN-3110, viral immunotherapy, clinical trials, prostate cancer, non-small cell lung cancer, pancreatic cancer, high-grade glioma, FDA, biopharmaceutical, enLIGHTEN Discovery Platform